Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
SwanBio

19.01.2021

SwanBio Therapeutics Appoints Alison Lawton to Board of Directors

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointment of Alison Lawton to the company’s Board of Directors.
SwanBio

06.01.2021

SwanBio Therapeutics Appoints Scott McMillan, Ph.D., as Chief Technical Officer

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Scott McMillan, Ph.D., has been appointed Chief Technical Officer.
SwanBio

20.11.2020

SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors. In addition to her role as a non-executive Director, Ms. Allen will serve as the Chair of SwanBio’s Audit Committee.
SwanBio

01.06.2020

SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer

SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experience to the SwanBio Therapeutics team, most recently serving as the CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases.
SwanBio

23.04.2020

SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene Therapy for Neurological Diseases

SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of AMN and other neurological diseases, today announces the successful completion of a $52 million expanded Series A financing.
Gyroscope
Freeline
SwanBio

23.10.2019

Building Syncona’s Gene Therapy Platform

Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.
Gyroscope
SwanBio
Freeline

23.10.2019

An Introduction to Gene Therapy

Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt, provide an introduction to gene therapy, a field where Syncona has developed deep domain expertise and built a strategic platform.